FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	
-------------	------	-------	--

ubject to	S
5	

TATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer s Section 16. Form 4 or Form obligations may continue. See Instruction 1(b) Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Zoghbi Huda Y (Last) (First) (Middle)						2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS, INC. [REGN]									k all appli Directo	cable) or (give title		erson(s) to Issuer 10% Owner Other (specify below)	
777 OLD SAW MILL RIVER ROAD						3. Date of Earliest Transaction (Month/Day/Year) 05/07/2020													
(Street) TARRYTOWN NY 10591					- 4. II	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indi Line) X	,				
(City)	(S	tate)	(Zip)												1 013011				
			le I - N			_			-	d, Di	sposed o			ially				1	
		2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a			and 5) Securit Benefic Owned		es ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
										v	Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Common	Stock			05/07/20)20		M		5,118	A	\$39	1.92	5,	5,761		D		
Common	Stock		05/07/2		2020	020			S		1,722	D	\$565	.64(1)	4,	4,039		D	
Common Stock		05/07/2020				S		2,128	D	\$566	.37 ⁽²⁾	²⁾ 1,911			D				
Common Stock		05/07/2020				S		646	D	\$567	.58 ⁽³⁾	1,265		D					
Common Stock			05/07/2020				S		609	D	\$568	68.37 ⁽⁴⁾		656		D			
Common	Stock			05/07/	2020	020		S		13	D	D \$569.2		643			D		
		Т	able II								posed of converti				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any		4. Transa Code (8)	ction	5. Number		6. Date Exerci Expiration Da (Month/Day/Y		isable and	7. Title and Amount of Securities Underlying Derivative Sect (Instr. 3 and 4)		8. D Si (li	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amou or Numb of Share	ber					
Non- Qualified Stock Option	\$391.92	05/07/2020			M			5,118	(5)		09/09/2026	Common Stock	5,11	18	\$0.0	10,235	5	D	

Explanation of Responses:

buy)

- 1. Represents volume-weighted average price of sales of 1,722 shares of Company stock on May 7, 2020 at prices ranging from \$565.43 to \$565.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 7, 2020 at each separate price.
- 2. Represents volume-weighted average price of sales of 2,128 shares of Company stock on May 7, 2020 at prices ranging from \$566.00 to \$566.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 7, 2020 at each separate price.
- 3. Represents volume-weighted average price of sales of 646 shares of Company stock on May 7, 2020 at prices ranging from \$567.20 to \$567.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 7, 2020 at each separate price.
- 4. Represents volume-weighted average price of sales of 609 shares of Company stock on May 7, 2020 at prices ranging from \$568.05 to \$568.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 7, 2020 at each separate price.
- 5. The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.

/s/**Huda Y. Zoghbi 05/07/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.